How do procurement agencies evaluate cost-effectiveness when selecting between RDTs and molecular assays for routine surveillance?

Agencies apply WHO-recommended threshold analyses comparing cost-per-correctly-diagnosed-case rather than unit price alone. Molecular assays demonstrate superior cost-effectiveness in low-transmission settings where RDT false-negative rates exceed 8–10% [21]. Read More

What regulatory pathway do AI-powered microscopy devices follow for WHO prequalification?

WHO's 2024 framework classifies AI-assisted diagnostics under the existing in-vitro diagnostics prequalification programme with additional algorithm validation requirements [6]. Manufacturers must submit field performance data from at least three endemic-country sites. Read More

How do HRP2 gene deletions affect RDT procurement strategies in East Africa?

National programs in affected regions are transitioning to dual-antigen tests detecting both HRP2 and pLDH antigens [7]. This shift increases per-test costs by approximately 15–20% but significantly reduces misdiagnosis risk. Read More

What role do private-sector pharmacies play in expanding diagnostic access in endemic countries?

Pharmacies in Nigeria, Uganda, and Myanmar now account for 12–18% of malaria tests performed under the WHO's test-treat-track policy [10]. Regulatory frameworks permitting pharmacy-based testing are expanding across West Africa. Read More

How are multiplexed fever panels positioned relative to standalone malaria tests?

Multiplexed panels command 3–4× higher pricing but reduce total diagnostic cost in co-endemic regions by eliminating sequential single-disease testing [14]. Adoption remains concentrated in hospital and diagnostic centre settings. Read More

What supply-chain risks could disrupt the Malaria Diagnostics Market through 2035?

Nitrocellulose membrane shortages and single-source antibody supply dependencies represent the primary vulnerabilities [11]. Manufacturers are diversifying suppliers and qualifying alternative membrane substrates. Read More

How does the transition from control to elimination phase change the diagnostic product mix?

Elimination-phase countries shift demand toward ultra-sensitive molecular assays and away from high-volume RDT procurement [4]. Per-capita diagnostic spending increases even as total test volumes decline. Read More

Malaria Diagnostics Market

ID: MRFR/LS/4971-HCR

100 Pages

Kinjoll Dey

Last Updated: June 22, 2026

Malaria Diagnostics Market Research Report: Size, Share, Trend Analysis By Technology (Rapid Diagnostic Tests, Microscopy, Polymerase Chain Reaction, Serology Tests, Loop-Mediated Isothermal Amplification), By End Users (Hospitals, Diagnostic Laboratories, Research Institutes, Home Care Settings), By Product Type (Test Kits, Reagents, Instruments), By Applications (Clinical Diagnosis, Epidemiological Studies, Drug Efficacy Studies) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Growth Outlook & Industry Forecast 2025 To 2035

Summary Table of Contents Segmentation Download PDF

Certified Researchers

Customize Report

1 Market Overview |
1. 1.1 Study Assumptions & Market Definition |
2. 1.2 Scope of the Study |
3. 1.3 Research Methodology
2 Market Summary & Key Takeaways
3 Market Dynamics |
1. 3.1 Market Drivers Analysis | |
  1. 3.1.1 Global Fund & PMI Procurement Expansion | |
  2. 3.1.2 HRP2/3 Gene Deletion Surveillance Mandates | |
  3. 3.1.3 Molecular Diagnostics Cost Reduction | |
  4. 3.1.4 AI-Enabled Microscopy Platforms | |
  5. 3.1.5 National Elimination Program Investments | |
  6. 3.1.6 Decentralized Community Health Testing | |
  7. 3.1.7 Dual-Antigen RDT Regulatory Approvals |
2. 3.2 Market Restraints Analysis | |
  1. 3.2.1 Declining Malaria Incidence in Elimination-Phase Countries | |
  2. 3.2.2 Counterfeit and Substandard Test Proliferation | |
  3. 3.2.3 Cold-Chain Limitations for Molecular Reagents | |
  4. 3.2.4 Health Workforce Capacity Constraints | |
  5. 3.2.5 Donor Fatigue and Funding Uncertainty |
3. 3.3 Market Opportunity Analysis | |
  1. 3.3.1 CRISPR-Based Point-of-Care Diagnostics | |
  2. 3.3.2 Digital Surveillance and Data Monetization | |
  3. 3.3.3 Private-Sector Retail Channel Expansion | |
  4. 3.3.4 Multiplexed Fever Panel Assays | |
  5. 3.3.5 Emerging Market Co-Financing Models |
4. 3.4 Industry Value Chain Analysis |
5. 3.5 Porter's Five Forces Analysis
4 Global Malaria Diagnostics Market Size & Forecast (2021–2035) |
1. 4.1 Historical Market Size (2021–2025) |
2. 4.2 Current & Forecast Market Size (2026–2035) |
3. 4.3 Market Size by Revenue (USD Billion) |
4. 4.4 Year-over-Year Growth Analysis
5 Segmentation Analysis |
1. 5.1 By Technology | |
  1. 5.1.1 Microscopy | |
  2. 5.1.2 RDTs (HRP2-Based Pf-Only RDTs and more) | |
  3. 5.1.3 Molecular Diagnostics (qPCR / Conventional PCR and more) | |
  4. 5.1.4 Next-Gen Platforms |
2. 5.2 By End User | |
  1. 5.2.1 Hospitals | |
  2. 5.2.2 Clinics | |
  3. 5.2.3 Diagnostic Centres | |
  4. 5.2.4 Community Health Posts
6 Regional Analysis |
1. 6.1 North America | |
  1. 6.1.1 United States | |
  2. 6.1.2 Canada | |
  3. 6.1.3 Mexico |
2. 6.2 Europe | |
  1. 6.2.1 Germany | |
  2. 6.2.2 United Kingdom | |
  3. 6.2.3 France | |
  4. 6.2.4 Italy | |
  5. 6.2.5 Spain | |
  6. 6.2.6 Nordic Countries | |
  7. 6.2.7 Russia | |
  8. 6.2.8 Rest of Europe |
3. 6.3 Asia-Pacific | |
  1. 6.3.1 China | |
  2. 6.3.2 India | |
  3. 6.3.3 Japan | |
  4. 6.3.4 South Korea | |
  5. 6.3.5 ASEAN | |
  6. 6.3.6 Rest of Asia-Pacific |
4. 6.4 South America | |
  1. 6.4.1 Brazil | |
  2. 6.4.2 Argentina | |
  3. 6.4.3 Rest of South America |
5. 6.5 Middle East & Africa | |
  1. 6.5.1 Saudi Arabia | |
  2. 6.5.2 UAE | |
  3. 6.5.3 South Africa | |
  4. 6.5.4 Egypt | |
  5. 6.5.5 Rest of MEA
7 Competitive Landscape |
1. 7.1 Market Share Analysis (2025) |
2. 7.2 Competitive Benchmarking Matrix |
3. 7.3 Company Profiles | |
  1. 7.3.1 Abbott Laboratories | |
  2. 7.3.2 bioMérieux SA | |
  3. 7.3.3 Access Bio Inc. | |
  4. 7.3.4 Sysmex Corporation | |
  5. 7.3.5 Bio-Rad Laboratories | |
  6. 7.3.6 Meridian Bioscience | |
  7. 7.3.7 Premier Medical Corporation | |
  8. 7.3.8 Hologic Inc. | |
  9. 7.3.9 Ortho Clinical Diagnostics | |
  10. 7.3.10 Siemens Healthineers
8 Future Outlook & Strategic Recommendations (2026–2035) |
1. 8.1 AI-Augmented Diagnostic Workflows |
2. 8.2 Elimination-Phase Surveillance Economics |
3. 8.3 Integrated Fever Management Platforms |
4. 8.4 Supply-Chain Localization and Regional Manufacturing
9 Recent Developments & News
10 Frequently Asked Questions (FAQs)
11 Report Scope & Methodology |
1. 11.1 Study Period & Base Year |
2. 11.2 Data Sources & Citations |
3. 11.3 Abbreviations
12 LIST OF TABLES |
TABLE 1 Global Malaria Diagnostics Market Size & Forecast, by Revenue (USD Billion), 2021–2035 |
TABLE 2 Global Malaria Diagnostics Market — Year-over-Year Growth Analysis, 2021–2035 |
TABLE 3 Global Malaria Diagnostics Market — Driver Impact Analysis |
TABLE 4 Global Malaria Diagnostics Market — Restraints Impact Analysis |
TABLE 5 Global Malaria Diagnostics Market Size, by Technology, 2021–2035 |
TABLE 6 Global Malaria Diagnostics Market Size, by End User, 2021–2035 |
TABLE 7 Global Malaria Diagnostics Market Size, by Region, 2021–2035 (USD Billion) |
TABLE 8 North America Malaria Diagnostics Market Size, by Country, 2021–2035 |
TABLE 9 Europe Malaria Diagnostics Market Size, by Country, 2021–2035 |
TABLE 10 Asia-Pacific Malaria Diagnostics Market Size, by Country, 2021–2035 |
TABLE 11 South America Malaria Diagnostics Market Size, by Country, 2021–2035 |
TABLE 12 Middle East & Africa Malaria Diagnostics Market Size, by Country, 2021–2035 |
TABLE 13 Competitive Benchmarking Matrix — Global Malaria Diagnostics Market, 2025 |
TABLE 14 Company Profiles — Key Players, Global Malaria Diagnostics Market |
TABLE 15 Recent Developments & Strategic Announcements, 2023–2025 |
TABLE 16 Report Scope & Methodology Summary |
TABLE 17 Detailed Sources and Citations
13 LIST OF FIGURES |
FIGURE 1 Global Malaria Diagnostics Market Dynamics — Drivers, Restraints, and Opportunities |
FIGURE 2 Malaria Diagnostics Industry Value Chain Analysis |
FIGURE 3 Porter's Five Forces Analysis — Malaria Diagnostics Market |
FIGURE 4 Global Malaria Diagnostics Market Size Trend (USD Billion), 2021–2035 |
FIGURE 5 Global Malaria Diagnostics Market Share, by Technology, 2025 |
FIGURE 6 Global Malaria Diagnostics Market Share, by End User, 2025 |
FIGURE 7 Global Malaria Diagnostics Market Share, by Region, 2025 |
FIGURE 8 North America Malaria Diagnostics Market Revenue Trend, 2021–2035 |
FIGURE 9 Europe Malaria Diagnostics Market Revenue Trend, 2021–2035 |
FIGURE 10 Asia-Pacific Malaria Diagnostics Market Revenue Trend, 2021–2035 |
FIGURE 11 South America Malaria Diagnostics Market Revenue Trend, 2021–2035 |
FIGURE 12 Middle East & Africa Malaria Diagnostics Market Revenue Trend, 2021–2035 |
FIGURE 13 Competitive Landscape — Malaria Diagnostics Market Share Analysis, 2025

Certified Researchers

Customize Report

Segmentation Quick Reference

Dimension	Sub-Segments	Dominant Segment	Fastest Growing Segment
Technology	Microscopy; RDTs (HRP2-Based Pf-Only RDTs and more); Molecular Diagnostics (qPCR / Conventional PCR and more); Next-Gen Platforms	RDTs	Molecular Diagnostics
End User	Hospitals; Clinics; Diagnostic Centres; Community Health Posts	Clinics	Diagnostic Centres
Region	North America; Europe; Asia-Pacific; South America; Middle East & Africa	Middle East & Africa	Asia-Pacific

Market Segmentation Overview

By Technology

Sub-Segment	Key Trend
Microscopy	Gradual displacement by automated digital platforms; retained as a confirmation standard in hospitals
RDTs (HRP2-Based Pf-Only RDTs and more)	Transition to dual-antigen formats addressing HRP2 gene deletions
Molecular Diagnostics (qPCR / Conventional PCR and more)	Cost compression enabling deployment in district-level laboratories
Next-Gen Platforms	CRISPR-based and AI-enabled assays entering regulatory pipelines

Rapid diagnostic tests remain the volume leader due to their suitability for resource-limited settings, while molecular diagnostics are capturing an increasing share of value as health systems prioritize sensitivity over simplicity in elimination-phase programs.

By End User

Sub-Segment	Key Trend
Hospitals	Severe malaria case management and subspeciation testing
Clinics	Primary point of parasitological confirmation under national testing mandates
Diagnostic Centres	Expanding referral networks and molecular confirmation protocols
Community Health Posts	Last-mile testing through integrated community case management programs

Clinics dominate consumption because most endemic-country testing guidelines require parasitological confirmation at the primary care level before antimalarial treatment is prescribed. Diagnostic centres are the fastest-growing end-user segment as molecular confirmation and quality assurance testing expand.

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”